A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing ...

The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last ...

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

Long-term 340B participation is linked to stronger financial assets, with much of the program’s recent growth flowing ...

The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny and congressional, judicial, and industry pressures.

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed ...

At a time when healthcare executives are being asked to stretch scarce federal resources as far as possible, the 340B Drug Pricing Program is a much-appreciated lifeline. Despite the program being ...

The 340B Drug Pricing Program (340B Program) is no stranger to controversy. We have previously covered the ongoing contract pharmacy legal battles and the new alternative dispute resolution process.

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.